A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Stanford University
University of Nebraska
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Massachusetts General Hospital
University of Washington
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
INSYS Therapeutics Inc
Northside Hospital, Inc.
Northside Hospital, Inc.
Vanderbilt-Ingram Cancer Center
Northside Hospital, Inc.
Mayo Clinic